Brief: Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
05/12/2023 12:41
Dec 5 (Reuters) - Trevi Therapeutics Inc TRVI.O :
* TREVI THERAPEUTICS ANNOUNCES THE INITIATION OF ITS PHASE
2B
CORAL CLINICAL TRIAL OF HADUVIO™ FOR CHRONIC COUGH IN IDIOPATHIC
PULMONARY FIBROSIS (IPF)
* TREVI THERAPEUTICS INC - EXPECT TO ENROLL APPROXIMATELY
160
SUBJECTS AND STUDY 3 DOSES OF HADUVIO AGAINST PLACEBO
Source text for Eikon: ID:nPn1mGpKSa
Further company coverage: TRVI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million